Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Valeritas (OTCMKTS:VLRXQ) and Bio-Rad Laboratories (NYSE:BIO) Financial Review
04:25am, Tuesday, 14'th Apr 2026
Valeritas (OTCMKTS:VLRXQ - Get Free Report) and Bio-Rad Laboratories (NYSE: BIO - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses ba
Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the
Allspring Global Investments Holdings LLC Decreases Stake in Bio-Rad Laboratories, Inc. $BIO
03:10am, Friday, 03'rd Apr 2026
Allspring Global Investments Holdings LLC cut its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 4.1% in the undefined quarter, according to the company in its most recent filing with the Secur
HOLMDEL, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, anno
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
04:15pm, Monday, 30'th Mar 2026
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified compa
Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tuesday, March 31st at 10am ET
07:58am, Wednesday, 25'th Mar 2026
BKYI: Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tues., Mar 31 at 10am ET. Dial-in: 1-877-418-5460
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
08:00am, Tuesday, 24'th Mar 2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced toda
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
04:58pm, Wednesday, 18'th Mar 2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company,
BIO-key Partners with TD SYNNEX Public Sector (DLT) to Deliver Identity-Bound Biometric and IAM Solutions to the U.S. Public Sector
07:57am, Thursday, 12'th Mar 2026
HOLMDEL, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions enablin
Fisher Asset Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. $BIO
04:20am, Wednesday, 04'th Mar 2026
Fisher Asset Management LLC trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 3.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 133,465 s
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients
04:01am, Tuesday, 03'rd Mar 2026
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients, cash position provides base for growth.
FibroBiologics to Present at the BIO Investment & Growth Summit
08:30am, Thursday, 26'th Feb 2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
10:16am, Friday, 20'th Feb 2026
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
09:36am, Thursday, 19'th Feb 2026
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of “Hold” by Brokerages
03:29am, Thursday, 19'th Feb 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One investment ana
